SAM
REGN icon

Sentinel Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sentinel Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-600
Closed -$326K – 271
2015
Q4 		$326K Buy
+600
New +$325K 0.01% 234

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sentinel Asset Management's REGN Position: Q1 2016 in Review

Sentinel Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 600 shares — an estimated $326K sold.

Sentinel Asset Management first reported a position in REGN in Q4 2015 and held it in 1 quarter. The position peaked at $326K in Q4 2015. 549 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

  • Sentinel Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Sentinel Asset Management sold 600 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $326K.
  • Sentinel Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Sentinel Asset Management's Regeneron Pharmaceuticals position peaked at $326K in Q4 2015.
  • 549 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Sentinel Asset Management's 13F filing for Q1 2016, filed 13 May 2016.